- Benzinga•14 hours ago
Myriad Genetics, Inc. (NASDAQ: MYGN ) is a molecular diagnostic company engaged in the development and marketing of transformative molecular diagnostic tests. The company recently announced a new relationship ...
- GlobeNewswire•17 hours agoMyriad’s BRACAnalysis CDx® Test Identifies Patients with Ovarian Cancer Who Would Benefit from Second-Line Maintenance Treatment with Olaparib
SALT LAKE CITY, Oct. 26, 2016-- Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, today announced that its BRACAnalysis CDx ® test accurately identified patients who may ...
- GlobeNewswire•2 days agoMyriad RBM Announces an Agreement with Sanofi to Measure Predictive Cardiovascular Biomarkers in Patients with Diabetes
SALT LAKE CITY, Oct. 25, 2016-- Myriad RBM, a wholly-owned subsidiary of Myriad Genetics, Inc., today announced that it will work with Sanofi, a global and diversified healthcare leader, to perform a biomarker ...
Myriad Genetics, Inc. (MYGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||19.01 x 200|
|Ask||20.28 x 100|
|Day's Range||19.43 - 19.86|
|52wk Range||17.66 - 46.24|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||11.42|
|Avg Vol (3m)||1,966,975|
|Dividend & Yield||N/A (N/A)|